FRIDAY, SEPTEMBER 30, 2016

Novartis donates 300 million malaria treatments for children

Novartis, which produces Coartem Dispersible, the first pediatric antimalarial treatment that has been pre-qualified by the World Health Organization, recently sent the treatment to more than 30 countries that are endemic with malaria.

Novartis began shipping the treatments in 2009. Since then, the company estimates that it has sent 300 million treatments to the malaria-endemic nations without receiving any profit.

“This milestone underscores our long-standing commitment to the fight against malaria and to the children who are most at risk from the disease,” Novartis CEO Joseph Jimenez said. “We are proud of the part we have played in helping to reduce childhood deaths from malaria. And we continue to provide medicine at no profit to people who need it, contributing to the goal of a world free from the disease.”

Most of the malaria treatments have been sent to the public sector and are meant to help children.

“This is a fantastic achievement and we are proud to have partnered with Novartis on the development of Coartem Dispersible, helping children who are most at risk of this deadly disease,” Medicines for Malaria Venture (MMV) Chief Executive Officer David Reddy said. “The WHO World Malaria Report 2015 shows that we are making significant strides in reducing child mortality from malaria, and this is largely thanks to sustained international commitment and the availability of a range of innovative tools and solutions, including quality child-friendly medicines like Coartem Dispersible. MMV applauds Novartis for making this important drug widely available on a no-profit basis to children in need and achieving this significant milestone.”

Organizations in this story

Novartis Corporate Communications 230 Park Avenue, 21st Floor NY, NY 10169

Get notified the next time we write about Novartis!